ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Monday

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Monday, September 15th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $5.90 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Monday, September 15, 2025 at 10:30 AM ET.3 personal care stocks that smell like good earnings playsImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. ImmunoPrecise Antibodies Trading Up 8.5%IPA opened at $2.10 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.85 and a debt-to-equity ratio of 0.49. The firm has a market cap of $96.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.53. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $3.25. The stock has a fifty day moving average price of $1.98 and a 200-day moving average price of $1.03. Wall Street Analyst Weigh InMarketBeat Week in Review – 07/31 - 08/04Separately, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, ImmunoPrecise Antibodies currently has an average rating of "Buy" and an average target price of $4.00.Check Out Our Latest Stock Analysis on IPAInstitutional Trading of ImmunoPrecise AntibodiesSmells Like New Highs for This Fragrance Boom WinnerA hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. XTX Topco Ltd increased its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 394.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,382 shares of the company's stock after purchasing an additional 72,897 shares during the period. XTX Topco Ltd owned approximately 0.20% of ImmunoPrecise Antibodies worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.70% of the company's stock. ImmunoPrecise Antibodies Company Profile (Get Free Report)ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.Read MoreFive stocks we like better than ImmunoPrecise AntibodiesStock Splits, Do They Really Impact Investors?Union Pacific: Laying the Tracks for America's Industrial RenewalWhat Are Growth Stocks and Investing in Them TransDigm’s Edge: From Spare Parts to Sky-High ProfitsRussell 2000 Index, How Investors Use it For Profitable TradingSpire Global: Tiny Satellites, Big Buy Ratings and UpsideThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in ImmunoPrecise Antibodies Right Now?Before you consider ImmunoPrecise Antibodies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here